Abstract
SY-5609 is a highly potent inhibitor of CDK7, a key regulator of cell cycle progression and transcription. Initial phase 1 results of SY-5609 in patients (pts) with advanced solid tumors reported proof of mechanism with dose-dependent effects on a pharmacodynamic (PD) gene expression marker POLR2A mRNA at 3 mg/day, the maximum tolerated dose (MTD) of the continuous daily dosing schedule. Additional data from the ongoing study, including from intermittent dosing schedules, are reported.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call